

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):

Results from the Real-World PARIS Registry

Roxana Mehran, MD, FESC

Professor of Medicine (Cardiology) and Health Evidence Policy Director of Interventional Cardiovascular Research and Clinical Trials The Icahn School of Medicine at Mount Sinai, New York, NY

on behalf of PARIS Investigators



Conflict of Interest:

Institutional Grant/Research Support:
Bristol-Myers Squibb/ Sanofi
Lilly/ DSI
The Medicines Company
BG Medicine

Consulting Fees/Honoraria

Sanofi

Abbott Vascular

Astra Zeneca

Merck

Regado Biosciences

Janssen (J+J)
BSC
Covidien
CSL Behring



Background and Rationale



- Antiplatelet agents are the cornerstone of therapy in patients with ACS and in those undergoing PCI
- Current ACC/AHA guidelines¹ recommend 30 days DAPT following placement of a BMS and 1 year following placement of a DES.
- In patients with ACS 12 months of DAPT is recommended regardless of stent type



DAPT Cessation and PCI: Existing Evidence



- Premature cessation of DAPT, within the first 6 months after PCI, has been associated with an increased risk of stent thrombosis.¹
- Sustained DAPT (one year or longer) has been associated with lower risk for adverse events in observational studies.^{2,3}
- Most studies involved select cohorts and limited by prespecified or standard criteria to define DAPT status

¹Schulz et al., EHJ 2009;²Ho et al., AHJ 2007;³Park et al., AJC 2006



DAPT Cessation and PCI: Unresolved Questions



- Does risk after DAPT cessation depend on the underlying context or clinical circumstances in which antiplatelet therapy is stopped (surgery vs. bleeding vs. physician-guidance)?
- How long does risk persist after antiplatelet therapy is withdrawn?
- What is the overall contribution of DAPT cessation on adverse events in the contemporary PCI era?



Study Design



- Multicenter, multinational, observational study
- 5,031 subjects were followed for approximately 24 months post stent implantation
- Included bare metal and drug-eluting stents
- All events, including all occurrences of DAPT cessation, were adjudicated by a <u>blinded external clinical events</u> <u>committee</u>



Modes of DAPT Cessation



Discontinuation

 patients had discontinued DAPT as per recommendation of their physician who felt the patient no longer needed therapy

Interruption

- patients had interrupted DAPT use on a voluntary basis and as guided by a physician due to (e.g. surgery)
- DAPT was then reinstituted within 14 days

Disruption

 patients had disrupted DAPT use due to bleeding or noncompliance.




5,031 Patients with successful PCI with stenting enrolled at 15 sites in the US and Europe



Heart

2-Year Kaplan-Meier Plot of Any DAPT Cessation




Time From PCI, Months



Incidence rates calculated over entire study population. Patients censored at last known contact, death or study end.


2-Year Kaplan-Meier Plots of Any Discontinuation, Interruption and Disruption





Incidence rates calculated over entire study population. Patients censored at last known contact, death or study end.

Overall Event Rates Over 2 Years





Incidence calculated as cumulative incidence from a Kaplan-Meier estimate of the time to the first occurrence of the adverse event.

Impact of DAPT Cessation on Adverse Events




DAPT Cessation and MACE*

		HR (95% CI)	ΡE	vents (n)
On-DAPT		1.00 (Ref)		413
Discontinuation		0.63 (0.46, 0.86)	0.004	52
Interruption		1.41 (0.94, 2.12)	0.101	26
Disruption		1.50 (1.14, 1.97)	0.004	67
0-7 Days		- 7.04 (3.31, 14.95)	<0.001	7
8-30 days		2.17 (0.97, 4.88)	0.06	6
31+ days		1.30 (0.97, 1.76)	0.083	54
0.25 0.5	1 2 4 8	16		
Hazard Ratio				

Mount Sinai Heart


*Cardiac Death, Def/Prob ST, Spontaneous MI, Clinically Driven TLR. All Cox Models adjusted for age, gender, region, ACS presentation, type of stent, number of stents implanted.

DAPT Cessation and Cardiac Death, Def/Prob ST, Spontaneous MI






DAPT Cessation and Spontaneous MI






DAPT Cessation and Def/Prob Stent Thrombosis





DAPT Cessation and Cardiac Death






Overall Contribution of DAPT Cessation on Adverse Events




Number (%) of Def/Prob ST events by DAPT Status*



*Out of 71 ST events at 2 years, 57 (80.3%) occurred while patients were ON DAPT. ST defined by the Academic Research Consortium (ARC) Critera.



Number (%) of Cardiac Death events by DAPT Status*



*Out of 148 Cardiac Death events at 2 years, 100 (67.6%) occurred while patients were ON DAPT. Cardiac Death defined using ARC criteria.



Conclusions

- The impact of DAPT cessation on cardiac risk after PCI is not uniform but varies substantially by underlying mode, a novel finding with important implications for future study design and clinical practice.
- Relative risk for MACE due to disruption is substantial, albeit short-lived, compared to those on DAPT.
- The overall impact of DAPT cessation on adverse events is modest and may have been mitigated with the introduction of safer stent platforms.
- Findings highlight the need for uniform approaches in classifying DAPT cessation, analogous to those currently used for bleeding and MI.



THELANCET-D-13-05217 S0140-6736(13)61720-1 Embargo: September 1, 2013—00.01 (BST)

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study

Roxana Mehran, Usman Baber, Philippe Gabriel Steg, Cono Ariti, Giora Weisz, Bernhard Witzenbichler, Timothy D Henry, Annapoorna S Kini, Thomas Stuckey, David J Cohen, Peter B Berger, Ioannis Iakovou, George Dangas, Ron Waksman, David Antoniucci, Samantha Sartori, Mitchell W Krucoff, James B Hermiller, Fayaz Shawl, C Michael Gibson, Alaide Chieffo, Maria Alu, David J Moliterno, Antonio Colombo, Stuart Pocock



13TL5217

This version saved: 16:45, 22-Aug-13

Articles

DM Version 3

